Assessment of Lipocalin 2, Clusterin, Soluble Tumor Necrosis Factor Receptor-1, Interleukin-6, Homocysteine, and Uric Acid Levels in Patients with Psoriasis

Overview

Journal Dis Markers

Publisher Wiley

Specialty Biochemistry

Date 2014 May 8

PMID 24803721

Citations 19

Authors

Arzu Ataseven

Recep Kesli

Gulcan Saylam Kurtipek

Perihan Ozturk

Affiliations

Soon will be listed here.

Abstract

Background: Chronic inflammation may play a role in psoriasis pathogenesis. Lipocalin 2, clusterin, soluble tumor necrosis factor receptor-1 (sTNFR-1), interleukin-6, homocysteine, and uric acid are inflammatory and/or biochemical markers. However, both the roles of these markers and the pathogenesis of psoriasis are unknown.

Objective: The aim of this study was to investigate serum levels of lipocalin 2, clusterin, sTNFR-1, interleukin-6, homocysteine, and uric acid in patients and controls groups.

Methods: Fifty-six patients with psoriasis and 33 healthy controls were included in the study. Serum concentrations of the markers were evaluated by ELISA. The Psoriasis Area and Severity Index (PASI) was evaluated in all psoriasis patients. Body mass index (BMI) was calculated by dividing weight (kg) by height (m) squared.

Results: The serum value of lipocalin and sTNFR-1 were significantly higher in psoriasis patients than in controls (resp., P < 0.001, P < 0.05). The others showed no significant differences between psoriasis and the control groups (all of them P > 0.05). The mean PASI score in the patient group was 8.3 ± 6.5.

Conclusions: These findings suggest that lipocalin 2 and sTNFR-1 might play a role in the pathogenesis of psoriasis and can be used as markers of the disease.

Citing Articles

Effect of weight loss and liraglutide on neutrophil gelatinase-associated lipocalin levels among individuals with overweight and knee osteoarthritis: Exploratory analyses of a randomized controlled trial.

Poulsen A, Stisen Z, Skougaard M, Christensen R, Overgaard A, Gudbergsen H Osteoarthr Cartil Open. 2025; 7(1):100562.

PMID: 39877802 PMC: 11773487. DOI: 10.1016/j.ocarto.2024.100562.

Is there still a place for neutrophil gelatinase-associated lipocalin to serve as a biomarker in psoriasis?.

Fratczak A, Lupicka-Slowik A, Sienczyk M, Polak K, Bergler-Czop B, Miziolek B Postepy Dermatol Alergol. 2025; 41(6):571-576.

PMID: 39877113 PMC: 11770581. DOI: 10.5114/ada.2024.142572.

Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial.

Petkovic-Dabic J, Binic I, Caric B, Bozic L, Umicevic-Sipka S, Bednarcuk N Biomolecules. 2025; 15(1).

PMID: 39858442 PMC: 11763288. DOI: 10.3390/biom15010046.

Coupling of Alzheimer's Disease Genetic Risk Factors with Viral Susceptibility and Inflammation.

Cao C, Fu G, Xu R, Li N Aging Dis. 2023; 15(5):2028-2050.

PMID: 37962454 PMC: 11346407. DOI: 10.14336/AD.2023.1017.

Significance of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) for the Monitoring of Treatment Response to Cyclosporine in Patients with Psoriasis.

Fratczak A, Miziolek B, Lupicka-Slowik A, Sienczyk M, Polak K, Bergler-Czop B Life (Basel). 2023; 13(9).

PMID: 37763277 PMC: 10532527. DOI: 10.3390/life13091873.

References

Cakmak S, Gul U, Kilic C, Gonul M, Soylu S, Kilic A . Homocysteine, vitamin B12 and folic acid levels in psoriasis patients. J Eur Acad Dermatol Venereol. 2009; 23(3):300-3. DOI: 10.1111/j.1468-3083.2008.03024.x. View

Koliadenko V, Chernyshov P . [Interleukin-6 as a marker of the activity of a pathological process in patients with psoriasis]. Lik Sprava. 2006; (5-6):80-2. View

Van Snick J . Interleukin-6: an overview. Annu Rev Immunol. 1990; 8:253-78. DOI: 10.1146/annurev.iy.08.040190.001345. View

Isha , Jain V, Lal H . C-reactive protein and uric Acid levels in patients with psoriasis. Indian J Clin Biochem. 2012; 26(3):309-11. PMC: 3162954. DOI: 10.1007/s12291-011-0132-4. View

Angelopoulos T, Lowndes J, Zukley L, Melanson K, Nguyen V, Huffman A . The effect of high-fructose corn syrup consumption on triglycerides and uric acid. J Nutr. 2009; 139(6):1242S-1245S. DOI: 10.3945/jn.108.098194. View

Severin E, Nave B, Stander M, Ott R, Traupe H . Total antioxidative capacity is normal in sera from psoriasis patients despite elevated bilirubin, tocopherol and urate levels. Dermatology. 1999; 198(4):336-9. DOI: 10.1159/000018171. View

Kumari S, Bonnet M, Ulvmar M, Wolk K, Karagianni N, Witte E . Tumor necrosis factor receptor signaling in keratinocytes triggers interleukin-24-dependent psoriasis-like skin inflammation in mice. Immunity. 2013; 39(5):899-911. DOI: 10.1016/j.immuni.2013.10.009. View

Brotas A, Cunha J, Lago E, Machado C, da Silva Carneiro S . Tumor necrosis factor-alpha and the cytokine network in psoriasis. An Bras Dermatol. 2012; 87(5):673-81. DOI: 10.1590/s0365-05962012000500001. View

Wang L, Erling P, Bengtsson A, Truedsson L, Sturfelt G, Erlinge D . Transcriptional down-regulation of the platelet ADP receptor P2Y(12) and clusterin in patients with systemic lupus erythematosus. J Thromb Haemost. 2004; 2(8):1436-42. DOI: 10.1111/j.1538-7836.2004.00854.x. View

10.

Serwin A, Sokolowska M, Chodynicka B . Soluble tumor necrosis factor alpha receptor type 1 in psoriasis patients treated with narrowband ultraviolet B. Photodermatol Photoimmunol Photomed. 2005; 21(4):210-1. DOI: 10.1111/j.1600-0781.2005.00164.x. View

11.

Coimbra S, Oliveira H, Reis F, Belo L, Rocha S, Quintanilha A . Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-α levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy. Br J Dermatol. 2010; 163(6):1282-90. DOI: 10.1111/j.1365-2133.2010.09992.x. View

12.

Gisondi P, Targher G, Cagalli A, Girolomoni G . Hyperuricemia in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2013; 70(1):127-30. DOI: 10.1016/j.jaad.2013.09.005. View

13.

Fattori E, Cappelletti M, Costa P, Sellitto C, Cantoni L, CARELLI M . Defective inflammatory response in interleukin 6-deficient mice. J Exp Med. 1994; 180(4):1243-50. PMC: 2191674. DOI: 10.1084/jem.180.4.1243. View

14.

Alenius G, Eriksson C, Rantapaa Dahlqvist S . Interleukin-6 and soluble interleukin-2 receptor alpha-markers of inflammation in patients with psoriatic arthritis?. Clin Exp Rheumatol. 2009; 27(1):120-3. View

15.

Chakraborty S, Kaur S, Guha S, Batra S . The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta. 2012; 1826(1):129-69. PMC: 3362670. DOI: 10.1016/j.bbcan.2012.03.008. View

16.

Sehgal P . Interleukin-6: molecular pathophysiology. J Invest Dermatol. 1990; 94(6 Suppl):2S-6S. DOI: 10.1111/1523-1747.ep12874963. View

17.

Lee J, Kye K, Seo E, Lee K, Lee S, Lim J . Expression of neutrophil gelatinase-associated lipocalin in calcium-induced keratinocyte differentiation. J Korean Med Sci. 2008; 23(2):302-6. PMC: 2526422. DOI: 10.3346/jkms.2008.23.2.302. View

18.

Seo S, Ahn J, Hong C, Seo E, Kye K, Lee W . Expression of neutrophil gelatinase-associated lipocalin in skin epidermis. J Invest Dermatol. 2005; 126(2):510-2. DOI: 10.1038/sj.jid.5700035. View

19.

Castells-Rodellas A, Castell J, Ramirez-Bosca A, Nicolas J, Valcuende-Cavero F, Thivolet J . Interleukin-6 in normal skin and psoriasis. Acta Derm Venereol. 1992; 72(3):165-8. DOI: 102340/0001555572165168. View

20.

Stejskal D, Karpisek M, Humenanska V, Hanulova Z, Stejskal P, Kusnierova P . Lipocalin-2: development, analytical characterization, and clinical testing of a new ELISA. Horm Metab Res. 2008; 40(6):381-5. DOI: 10.1055/s-2008-1062746. View